- Benson, Al B;
- Venook, Alan P;
- Al-Hawary, Mahmoud M;
- Cederquist, Lynette;
- Chen, Yi-Jen;
- Ciombor, Kristen K;
- Cohen, Stacey;
- Cooper, Harry S;
- Deming, Dustin;
- Engstrom, Paul F;
- Garrido-Laguna, Ignacio;
- Grem, Jean L;
- Grothey, Axel;
- Hochster, Howard S;
- Hoffe, Sarah;
- Hunt, Steven;
- Kamel, Ahmed;
- Kirilcuk, Natalie;
- Krishnamurthi, Smitha;
- Messersmith, Wells A;
- Meyerhardt, Jeffrey;
- Miller, Eric D;
- Mulcahy, Mary F;
- Murphy, James D;
- Nurkin, Steven;
- Saltz, Leonard;
- Sharma, Sunil;
- Shibata, David;
- Skibber, John M;
- Sofocleous, Constantinos T;
- Stoffel, Elena M;
- Stotsky-Himelfarb, Eden;
- Willett, Christopher G;
- Wuthrick, Evan;
- Gregory, Kristina M;
- Freedman-Cass, Deborah A
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.
